Mersana, GSK Option Co-development of Immunosynthen ADC Targeting HER2

 

• GSK receives exclusive global license option for XMT-2056

• Mersana to receive $100 million upfront option purchase fee

• If GSK exercises its option, Mersana to receive exercise payment; potential for additional development, regulatory and commercial milestone payments, plus tiered double-digit royalties on net sales

• Mersana to co-develop XMT-2056; retains options for U.S. profit-sharing and U.S. co-promotion

• Conference call today at 4:30 p.m. ET

Mersana will host a conference call today at 4:30 p.m. ET to discuss this collaboration, other business updates and its financial results for the second quarter of 2022. To access the call, please dial 646-307-1963 (domestic) or 800-715-9871 (international) and provide the Conference ID 4656534. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for at least 90 days.

https://finance.yahoo.com/news/mersana-therapeutics-announces-option-agreement-200200485.html